Oxurion NV
OXUR | BR
Overview
Corporate Details
- ISIN(s):
- BE0974487192
- LEI:
- 549300VWY8KVDFKLDM59
- Country:
- Belgium
- Address:
- Gaston Geenslaan 1, 3001 Heverlee
- Website:
- https://oxurion.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME. Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-19 08:30 |
Regulatory News Service
UK_OXURION_PR-LOI-_MICROBIOTE_EXE_EN.pdf
|
English | 278.4 KB | |
| 2025-06-19 08:30 |
Regulatory News Service
FR_OXURION_PR-LOI-_MICROBIOTE_EXE_FR.pdf
|
French | 279.2 KB | |
| 2025-06-19 08:30 |
Regulatory News Service
NL-OXURION_PR-LOI-_MICROBIOTE_EXE_NL.pdf
|
Dutch | 269.0 KB | |
| 2025-06-18 18:00 |
Regulatory News Service
OXUR-Transparency-Notification-EN-20250618.pdf
|
English | 326.1 KB | |
| 2025-06-18 18:00 |
Regulatory News Service
OXUR-Transparency-Notification-NL-20250618.pdf
|
Dutch | 347.4 KB | |
| 2025-06-12 08:30 |
Regulatory News Service
EN_OXURION_PR_Axiodi_Condition suspensive_EN.pdf
|
English | 192.4 KB | |
| 2025-06-12 08:30 |
Regulatory News Service
FR_OXURION_PR_Axiodi_Condition suspensive_FR.pdf
|
French | 131.8 KB | |
| 2025-06-12 08:30 |
Regulatory News Service
NL_OXURION_PR_Axiodi_Condition suspensive_NL.pdf
|
Dutch | 197.2 KB | |
| 2025-06-04 18:00 |
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250604.pdf
|
English | 263.5 KB | |
| 2025-06-04 18:00 |
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250604.pdf
|
Dutch | 363.1 KB | |
| 2025-05-22 18:00 |
AGM Report
Oxurion NV_Minutes AGM_20240513_exe.pdf
|
Dutch | 352.7 KB | |
| 2025-05-16 08:30 |
Regulatory News Service
EN_OXURION_ACQUISITION_AXIODIS_EN_exe.pdf
|
English | 421.6 KB | |
| 2025-05-16 08:30 |
Regulatory News Service
FR_OXURION_ACQUISITION_AXIODIS_exe.pdf
|
French | 428.4 KB | |
| 2025-05-16 08:30 |
Regulatory News Service
NL_OXURION_ACQUISITION_AXIODIS_NL_exe.pdf
|
Dutch | 462.7 KB | |
| 2025-03-18 18:30 |
Regulatory News Service
OXURION_PR-LOI-CRO_EN_180325.pdf
|
English | 232.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-03-07 | Bareldam SA | Close relation | Buy | 1,180,555 | 1,700,000.00 EUR |
| 2021-09-30 | Lavinia D. Clay 2009 Revocable Trust | Close relation | Other | 2,766,337 | 5,601,002.52 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |